Following last month’s $7.8 billion purchase of CAR T biotech Arcellx, Gilead’s dealmaking train chugs along with yet another acquisition—this time securing Ouro Medicines’ pipeline of T cell engagers for inflammatory diseases.

Original title: “Gilead Drops $2.1B for Ouro, Hopes To Split Cost with Galapagos”

Invea Therapeutics, a clinical-stage biotech developing oral small molecules for inflammatory diseases, withdrew its plan for an initial public offering on Friday, citing market conditions. Invea Therapeutics, a clinical-stage biotech developing oral small molecules for inflammatory diseases, withdrew its plan for an initial public offering on Friday, citing market conditions. - Renaissance Capital Invea Therapeutics, a clinical-stage biotech developing oral small molecules for inflammatory diseases, withdrew its plan for an initial public offering on Friday, citing market conditions. It had filed to raise $35 million by offering 3.2 million shares at a price range of $10 to $12.

Original title: “INAI IPO News - Inflammatory disease biotech Invea Therapeutics withdraws $35 million IPO”

Generate’s performance came on a day in which the broader financial markets plummeted on news of a higher-than-expected increase during January in the “core” producer price index (PPI) which excludes food and energy prices. Generate carried out the largest biotech IPO so far this year, saying that proceeds from the offering will be used toward clinical trials, as well as platform and pipeline R&D efforts. [Nasdaq] Generate:Biomedicines aims to build on pipeline now focused on cancer, I&I candidates, with plans to use proceeds toward funding clinical trials, platform and therapy R&D GEN – Genetic Engineering and Biotechnology News ... [Front row, center:] Generate: Biomedicines CEO Michael Nally and Jason Silvers, MD, JD, president and chief financial officer, lead a team of employees in celebrating the artificial intelligence (AI)-based platform and drug developer’s $400 million initial public offering (IPO) Friday on the Nasdaq Global Market. Generate:Biomedicines (NASDAQ: GENB), the drug developer focused on creating immunology and inflammation (I&I) and oncology treatments through its own artificial intelligence (AI)-based platform, has launched the year’s largest biotech initial public offering (IPO) to date, raising $400 million in gross proceeds toward clinical trials, as well as platform and pipeline R&D efforts. Among the next two highest biotech IPOs, late-stage oncology and neuroscience drug developer Eikon Therapeutics (NASDAQ: EIKN) raised $381 million gross proceeds priced on February 4, while radiopharma drug developer Aktis Oncology (NASDAQ: AKTS) racked up $318 million in gross proceeds priced on January 8.

Original title: “StockWatch: AI Drug Developer Generates $400M IPO”

US IPOs today: Once Upon a Farm, AgomAb and SpyGlass line up as fresh listings test demand - TechStock² The company intends to use the funds to repay debt, purchase equipment, and support other corporate expenses. Goldman Sachs and J.P. Morgan are steering the transaction. 3 · Belgian biotech AgomAb Therapeutics, which specializes in immunology and inflammatory diseases, set its IPO price at $16 per American depositary share — those U.S.-listed certificates that stand for foreign company stock. Cambridge Acquisition’s units hovered at $9.98, with SPACSphere’s units just above at $10.04. 7 · The week kicked off with a mixed bag of debuts. Electrical equipment maker Forgent Power Solutions, which pulled in $1.51 billion in its IPO, gained roughly 8.4% to $31.44. Furniture retailer Bob’s Discount Furniture climbed 5.6% to $17.98, while biotech firm Eikon Therapeutics slipped 1.2% to $14.82. Once Upon a Farm, the children’s food brand connected to actress Jennifer Garner, is gearing up for its NYSE debut on Friday. The company priced its U.S. IPO at $18 per share. Friday’s slate may not be a blockbuster, but it offers a clear snapshot of risk appetite — with consumer, biotech, and blank-check stocks all hitting the market. ASX IPO watch: MB Gold pops on debut after selloff as next floats line up View all · Bonduelle Reports January 2026 Share and Voting Rights Totals · February 6, 2026, 1:04 PM EST. Bonduelle, a French partnership limited by shares, disclosed its monthly information on January 31, 2026.

Original title: “US IPOs today: Once Upon a Farm, AgomAb and SpyGlass line up as fresh listings test demand”